Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27789664 | 0.95 | MAPT (0.48) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL27768325 | 0.87 | LMNA (0.53) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL27768385 | 0.87 | LMNA (0.60) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL28114539 | 0.82 | RAB9A (0.53) | MAPTRAB9ANPC1POLBTDP1 | |
| SCHEMBL25336331 | 0.79 | MKNK2 (0.43) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL1249806 | 0.77 | RAB9A (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL9975998 | 0.77 | RAB9A (0.76) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL29110788 | 0.76 | MAPT (0.51) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL28944524 | 0.76 | AR (0.49) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL29114965 | 0.75 | DYRK1A (0.51) | MAPTMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4472959-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148481-A1 | SMO MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2023-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136559-A1 | SMO MODULATOR COMPOUNDS | SMO, SHH, GLI1 | MAPT 4299/4885MEN1 1401/4885KMT2A 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.